RECRUITING

Promoting Alcohol Treatment Engagement Post-hospitalization

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is a 3-arm randomized clinical trial to evaluate the effectiveness of hospital-initiated Alcohol Use Disorder treatment, involving a Brief Negotiated Interview (with referral and telephone booster) alone, BNI+facilitated provision of MAUD, BNI+facilitated provision of MAUD+CBT4CBT on AUD treatment engagement, alcohol use and healthcare utilization.

Official Title

Promoting Alcohol Treatment Engagement Post-hospitalization With Brief Intervention, Medications and CBT4CBT: A Randomized Clinical Trial in a Diverse Patient Population.

Quick Facts

Study Start:2022-09-13
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05338151

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * hospitalized at Yale New Haven Hospital (YNHH)
  2. * meet Diagnostic and Statistical Manual (DSM-5) criteria for a moderate to severe AUD (regardless of primary reason for hospitalization) consistent with clinical guidelines for MAUD initiation
  3. * \>1 heavy drinking day by TLFB in 30 days prior to hospitalization
  4. * willing to consider MAUD
  5. * willing and able to be contacted for follow-up
  6. * provide written informed consent
  1. * have been engaged in formal AUD treatment in the past 30 days (i.e., excluding mutual help groups, such as Alcoholics Anonymous)
  2. * meet DSM-5 criteria for untreated moderate to severe opioid use disorder
  3. * self-reported or urine testing confirming pregnancy, nursing, or trying to conceive
  4. * life-threatening or unstable medical, surgical, or psychiatric condition that prohibits study participation
  5. * inability to provide \>1 collateral contact for a friend or family member
  6. * anticipate being unable to return for follow-up assessments for any reason, such as travel, incarceration, planned procedure
  7. * inability to understand English or Spanish.

Contacts and Locations

Study Contact

Yudilyn Jaramillo, MPH
CONTACT
203-314-2934
yudilyn.jaramillo@yale.edu

Principal Investigator

E. Jennifer Edelman, MD
PRINCIPAL_INVESTIGATOR
Yale University
Brian Kiluk, PhD
PRINCIPAL_INVESTIGATOR
Yale University

Study Locations (Sites)

Yale New Haven Hospital
New Haven, Connecticut, 06510
United States

Collaborators and Investigators

Sponsor: Yale University

  • E. Jennifer Edelman, MD, PRINCIPAL_INVESTIGATOR, Yale University
  • Brian Kiluk, PhD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-13
Study Completion Date2026-12

Study Record Updates

Study Start Date2022-09-13
Study Completion Date2026-12

Terms related to this study

Keywords Provided by Researchers

  • CBT4CBT
  • Brief Negotiated Interview (BNI)
  • Medication for alcohol use disorder (MAUD)
  • Phosphatidylethanol (PEth)

Additional Relevant MeSH Terms

  • Alcohol Use Disorder